Skip to main content
PegBio Co., Ltd. logo

PegBio Co., Ltd. — Investor Relations & Filings

Ticker · 2565 ISIN · CNE100006T44 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 2,125 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2565

About PegBio Co., Ltd.

http://www.pegbio.com

PegBio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies for chronic diseases, primarily focusing on the endocrine and metabolic fields. The company leverages its proprietary HECTORTM technology system to design and screen novel molecular entities, including peptide, protein, and small-molecule drugs, targeting unmet clinical needs. PegBio's robust pipeline addresses major chronic conditions such as Type 2 Diabetes (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Key pipeline assets include long-acting GLP-1 receptor agonists, such as Vepinatide, developed for T2DM treatment and weight management. The company emphasizes creating complementary, multi-benefit product pipelines characterized by new targets, new sites, and new mechanisms of action.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Regulatory Filings
2026-05-19 English
(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (3) NON-COMPLIANCE WITH LISTING RULES
Regulatory Filings
2026-05-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-06 English
2025 Annual Report
Regulatory Filings
2026-04-28 English
INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION BY THE COMPANY
Share Issue/Capital Change Classification · 75% confidence The document is an exchange announcement made under the Listing Rules and Inside Information Provisions regarding the CSRC’s filing notice for the company’s H Share full circulation application. It is not a financial report, earnings release, or management discussion, but rather a regulatory update on the conversion of unlisted shares to H shares and the intended listing of those shares. This constitutes a change in the company’s capital structure. Accordingly, it falls under “Share Issue/Capital Change (SHA).”
2026-04-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 90% confidence The document is the HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Listing Rules. It provides routine share capital and public float confirmations for the month ended 31 March 2026. It is a compliance filing submitted to the exchange, not an earnings release, management discussion, or capital-raising announcement. It does not announce the publication of another report but is itself a regulatory submission. It therefore falls under the fallback category “Regulatory Filings (RNS).”
2026-04-08 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.